SAN DIEGO, Calif., Oct. 13, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will webcast its Quarterly Update Conference Call for the third quarter of 2009 on Tuesday, October 20, 2009 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin''s president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the third quarter of 2009.
The call will be webcast live through Amylin''s corporate Web site and a recording will be made available following the close of the call. To access the webcast, please log on to http://www.amylin.com/ approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (866) 730-5763 (U.S./Canada) or (857) 350-1587 (international), conference access code 44746855. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (888) 286-8010 (U.S./Canada) or (617) 801-6888 (international), conference access code 78094555.
About Amylin
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin''s research and development activities leverage the Company''s expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com/.
Amylin Pharmaceuticals, Inc.
CONTACT: Media, Alice Izzo, +1-858-642-7272, alice.izzo@amylin.com, or
Investors, Michael York, +1-858-458-8602, michael.york@amylin.com, both of
Amylin Pharmaceuticals, Inc.
Web Site: http://www.amylin.com/
